Assertio Holdings, Inc. (ASRT) 10-Year Financial Performance & Capital Metrics

ASRT • • Industrial / General

HealthcareSpecialty & Generic PharmaSpecialty PharmaceuticalsPain Management

AboutAssertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.Show more

Revenue $125M -17.8%
EBITDA $1M +100.6%
Net Income -$22M +93.5%
EPS (Diluted) -0.23 +95.1%
Gross Margin 68.61% -16.6%
EBITDA Margin 1.08% +100.8%
Operating Margin -19.59% +87.8%
Net Margin -17.27% +92.1%
ROE -16.66% +90.9%
ROIC -17.08% +84.5%
Debt/Equity 0.33 +15.7%
Interest Coverage -8.05 +88.8%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓FCF machine: 21.1% free cash flow margin
✓Momentum leader: RS Rating 99 (top 1%)
✓Trading near 52-week high

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Sales declining 11.5% over 5 years
✗Shares diluted 34.1% in last year

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-10.77%

5Y-11.45%

3Y4.02%

TTM9.21%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM57.77%

EPS CAGR

10Y-

5Y-

3Y-

TTM57.45%

ROCE

10Y Avg-15.64%

5Y Avg-24.01%

3Y Avg-31.08%

Latest-13.48%

Peer Comparison

Pain Management

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
COLLCollegium Pharmaceutical, Inc.	1.48B	46.90	25.22	11.41%	7.72%	21.27%	13.71%	3.75
PRFXPainReform Ltd.	3.21M	0.82	-0.03			-48.4%		0.02
PCRXPacira BioSciences, Inc.	848.72M	20.65	-9.60	3.85%	2.99%	2.95%	21.06%	0.82
APUSApimeds Pharmaceuticals US, Inc	21.76M	1.73	-15.73			-63.2%
ASRTAssertio Holdings, Inc.	71.42M	11.13	-48.39	-17.83%	-21.06%	-27.34%	36.98%	0.33

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	342.74M	455.9M	380.72M	311.77M	229.53M	108.08M	111.01M	156.23M	152.07M	124.96M
Revenue Growth %	-0.12%	0.33%	-0.16%	-0.18%	-0.26%	-0.53%	0.03%	0.41%	-0.03%	-0.18%
Cost of Goods Sold+	67.9M	87.41M	72.6M	18.48M	9.51M	15.77M	15.83M	18.75M	27.02M	39.23M
COGS % of Revenue	0.2%	0.19%	0.19%	0.06%	0.04%	0.15%	0.14%	0.12%	0.18%	0.31%
Gross Profit+	274.84M	368.48M	308.13M	293.29M	220.02M	92.3M	95.18M	137.49M	125.05M	85.73M
Gross Margin %	0.8%	0.81%	0.81%	0.94%	0.96%	0.85%	0.86%	0.88%	0.82%	0.69%
Gross Profit Growth %	-0.27%	0.34%	-0.16%	-0.05%	-0.25%	-0.58%	0.03%	0.44%	-0.09%	-0.31%
Operating Expenses+	355.14M	343.97M	337.06M	229.03M	414.45M	174.46M	85.76M	98.08M	368.58M	110.21M
OpEx % of Revenue	1.04%	0.75%	0.89%	0.73%	1.81%	1.61%	0.77%	0.63%	2.42%	0.88%
Selling, General & Admin	199.35M	204.5M	195.69M	119.22M	110.44M	104.22M	56.55M	48.1M	69.74M	76.95M
SG&A % of Revenue	0.58%	0.45%	0.51%	0.38%	0.48%	0.96%	0.51%	0.31%	0.46%	0.62%
Research & Development	72.44M	32.63M	38.62M	8.04M	10.11M	4.21M	0	0	2.84M	3.82M
R&D % of Revenue	0.21%	0.07%	0.1%	0.03%	0.04%	0.04%	-	-	0.02%	0.03%
Other Operating Expenses	599K	106.84M	102.75M	101.77M	293.9M	66.03M	29.2M	49.98M	296M	29.44M
Operating Income+	-50.4M	24.51M	-42.18M	43.66M	-194.43M	-82.16M	9.42M	39.41M	-243.54M	-24.48M
Operating Margin %	-0.15%	0.05%	-0.11%	0.14%	-0.85%	-0.76%	0.08%	0.25%	-1.6%	-0.2%
Operating Income Growth %	-1.21%	1.49%	-2.72%	2.04%	-5.45%	0.58%	1.11%	3.18%	-7.18%	0.9%
EBITDA+	32.94M	133.88M	63.32M	150.09M	-91.48M	-55.72M	38.54M	72.8M	-215.31M	1.35M
EBITDA Margin %	0.1%	0.29%	0.17%	0.48%	-0.4%	-0.52%	0.35%	0.47%	-1.42%	0.01%
EBITDA Growth %	-0.87%	3.06%	-0.53%	1.37%	-1.61%	0.39%	1.69%	0.89%	-3.96%	1.01%
D&A (Non-Cash Add-back)	83.34M	109.38M	105.5M	106.43M	102.95M	26.43M	29.11M	33.4M	28.23M	25.83M
EBIT	-49.8M	19.22M	-30.37M	106.86M	-5.11M	-42.71M	9.67M	56.77M	24.94M	-20.68M
Net Interest Income+	-72.84M	-83.23M	-73.55M	-67.56M	-58.39M	-15.93M	-10.22M	-7.96M	-3.38M	182K
Interest Income	599K	485K	0	1.2M	0	0	0	0	0	3.22M
Interest Expense	73.44M	83.72M	73.55M	68.76M	58.39M	15.93M	10.22M	7.96M	3.38M	3.04M
Other Income/Expense	-72.84M	-89.01M	-61.74M	-5.68M	-17.49M	71.38M	-9.98M	-8.24M	-10.52M	2.95M
Pretax Income+	-123.24M	-64.5M	-103.92M	37.98M	-211.92M	-10.78M	-553K	31.17M	-254.05M	-21.53M
Pretax Margin %	-0.36%	-0.14%	-0.27%	0.12%	-0.92%	-0.1%	-0%	0.2%	-1.67%	-0.17%
Income Tax+	-47.5M	24.22M	-1.43M	1.07M	5.28M	17.37M	728K	-78.46M	77.89M	52K
Effective Tax Rate %	0.61%	1.38%	0.99%	0.97%	1.02%	2.61%	2.32%	3.52%	1.31%	1%
Net Income+	-75.74M	-88.72M	-102.5M	36.91M	-217.2M	-28.14M	-1.28M	109.63M	-331.94M	-21.58M
Net Margin %	-0.22%	-0.19%	-0.27%	0.12%	-0.95%	-0.26%	-0.01%	0.7%	-2.18%	-0.17%
Net Income Growth %	-1.57%	-0.17%	-0.16%	1.36%	-6.88%	0.87%	0.95%	86.58%	-4.03%	0.93%
Net Income (Continuing)	-75.74M	-88.72M	-102.5M	36.91M	-217.2M	-28.14M	-1.28M	109.63M	-331.94M	-21.58M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-5.04	-5.79	-6.54	2.30	-12.29	-1.07	-0.03	2.03	-4.67	-0.23
EPS Growth %	-1.61%	-0.15%	-0.13%	1.35%	-6.34%	0.91%	0.97%	69.35%	-3.3%	0.95%
EPS (Basic)	-5.04	-5.80	-6.54	2.31	-12.29	-1.07	-0.03	2.33	-4.67	-0.23
Diluted Shares Outstanding	15.03M	15.32M	15.68M	16.05M	17.68M	26.21M	43.17M	54.67M	71.03M	95.27M
Basic Shares Outstanding	15.03M	15.3M	15.68M	15.95M	17.68M	26.21M	43.17M	47M	71.03M	95.27M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	316.65M	307.66M	231.72M	215.92M	103.95M	94.25M	103.5M	132.26M	171.06M	202.55M
Cash & Short-Term Investments	209.77M	177.42M	128.09M	110.95M	42.11M	20.79M	36.81M	64.94M	73.44M	100.05M
Cash Only	209.77M	177.42M	128.09M	110.95M	42.11M	20.79M	36.81M	64.94M	73.44M	50.59M
Short-Term Investments	0	0	0	0	0	0	0	0	0	49.47M
Accounts Receivable	78.05M	102.59M	72.48M	37.21M	42.74M	44.35M	43.75M	45.36M	47.66M	54.12M
Days Sales Outstanding	83.11	82.13	69.49	43.56	67.97	149.78	143.85	105.96	114.4	158.08
Inventory	10.49M	13.03M	13.04M	3.4M	3.41M	11.71M	7.49M	13.7M	37.69M	38.31M
Days Inventory Outstanding	56.41	54.42	65.57	67.09	131.02	271.04	172.66	266.64	509.08	356.45
Other Current Assets	0	0	0	0	0	0	608K	0	299K	10.07M
Total Non-Current Assets+	1.05B	917.67M	806.9M	716.95M	423.22M	209.02M	223.05M	281.65M	115.36M	82.18M
Property, Plant & Equipment	14.79M	15.53M	13.02M	13.06M	3.5M	4.39M	2.26M	881K	2.04M	1.71M
Fixed Asset Turnover	23.17x	29.36x	29.23x	23.86x	65.64x	24.61x	49.08x	177.34x	74.58x	73.03x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	1.01B	902.15M	793.87M	692.1M	400.54M	200.08M	216.05M	198M	111.33M	80.47M
Long-Term Investments	-7.68M	0	0	11.78M	13.06M	1.58M	1.58M	268K	0	0
Other Non-Current Assets	7.68M	0	0	7.81M	6.12M	2.97M	3.15M	2.3M	1.99M	1K
Total Assets+	1.36B	1.23B	1.04B	932.87M	527.17M	303.27M	326.55M	413.91M	286.42M	284.73M
Asset Turnover	0.25x	0.37x	0.37x	0.33x	0.44x	0.36x	0.34x	0.38x	0.53x	0.44x
Asset Growth %	0.92%	-0.1%	-0.15%	-0.1%	-0.43%	-0.42%	0.08%	0.27%	-0.31%	-0.01%
Total Current Liabilities+	196.79M	221.77M	224.4M	124.9M	184.55M	132.69M	135.02M	95.32M	93.44M	114.69M
Accounts Payable	12.8M	14.86M	14.73M	6.14M	16.19M	14.81M	6.68M	5.99M	13.44M	14.74M
Days Payables Outstanding	68.84	62.03	74.07	121.26	621.82	342.69	154.12	116.64	181.54	137.12
Short-Term Debt	563.47M	466.05M	82.5M	120M	80M	11.94M	12.17M	470K	0	0
Deferred Revenue (Current)	1000K	1000K	1000K	-1000K	1000K	0	0	0	0	0
Other Current Liabilities	-559.31M	-460.52M	13.29M	2.71M	-82.5M	20.02M	47.65M	30.36M	6.09M	96.36M
Current Ratio	1.61x	1.39x	1.03x	1.73x	0.56x	0.71x	0.77x	1.39x	1.83x	1.77x
Quick Ratio	1.56x	1.33x	0.97x	1.70x	0.54x	0.62x	0.71x	1.24x	1.43x	1.43x
Cash Conversion Cycle	70.69	74.53	60.99	-10.61	-422.83	78.13	162.39	255.97	441.94	377.41
Total Non-Current Liabilities+	851.58M	752.78M	644.71M	587.63M	284.66M	115.07M	89.11M	92.87M	54.97M	48.96M
Long-Term Debt	800.33M	718.78M	544.23M	446.11M	271.26M	72.16M	61.32M	66.4M	38.21M	38.81M
Capital Lease Obligations	0	0	0	0	4.82M	2.81M	397K	0	1.47M	1.12M
Deferred Tax Liabilities	0	0	0	0	0	0	0	4.27M	4.55M	0
Other Non-Current Liabilities	22.24M	28.53M	14.3M	20.39M	8.58M	40.1M	27.4M	22.2M	10.74M	9.03M
Total Liabilities	1.05B	974.55M	869.11M	712.53M	469.21M	247.76M	224.13M	188.19M	148.42M	163.65M
Total Debt+	806.51M	718.78M	626.73M	566.11M	358.17M	89.6M	75.87M	66.87M	39.68M	40.27M
Net Debt	596.74M	541.36M	498.64M	455.16M	316.06M	68.81M	39.06M	1.93M	-33.77M	-10.32M
Debt / Equity	2.56x	2.87x	3.70x	2.57x	6.18x	1.61x	0.74x	0.30x	0.29x	0.33x
Debt / EBITDA	24.48x	5.37x	9.90x	3.77x	-	-	1.97x	0.92x	-	29.76x
Net Debt / EBITDA	18.11x	4.04x	7.87x	3.03x	-	-	1.01x	0.03x	-	-7.63x
Interest Coverage	-0.69x	0.29x	-0.57x	0.63x	-3.33x	-5.16x	0.92x	4.95x	-72.05x	-8.05x
Total Equity+	315.06M	250.79M	169.51M	220.34M	57.96M	55.51M	102.41M	225.72M	138M	121.08M
Equity Growth %	-0.14%	-0.2%	-0.32%	0.3%	-0.74%	-0.04%	0.84%	1.2%	-0.39%	-0.12%
Book Value per Share	20.96	16.37	10.81	13.73	3.28	2.12	2.37	4.13	1.94	1.27
Total Shareholders' Equity	315.06M	250.79M	169.51M	220.34M	57.96M	55.51M	102.41M	225.72M	138M	121.08M
Common Stock	264.51M	291.63M	313.86M	6K	8K	3K	4K	5K	9K	9K
Retained Earnings	-28.02M	-116.74M	-219.51M	-182.6M	-399.8M	-427.94M	-429.23M	-319.6M	-651.54M	-673.12M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-54K	-19K	-5K	-5K	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	143.89M	65.5M	62.17M	72.5M	90.47M	-65.57M	5.52M	78.6M	49.6M	26.41M
Operating CF Margin %	0.42%	0.14%	0.16%	0.23%	0.39%	-0.61%	0.05%	0.5%	0.33%	0.21%
Operating CF Growth %	3.57%	-0.54%	-0.05%	0.17%	0.25%	-1.72%	1.08%	13.23%	-0.37%	-0.47%
Net Income	-75.74M	-88.72M	-102.5M	36.91M	-217.2M	-28.14M	-1.28M	109.63M	-331.94M	-21.58M
Depreciation & Amortization	85.74M	109.38M	105.5M	106.43M	102.95M	26.43M	29.08M	33.4M	28.23M	25.83M
Stock-Based Compensation	14.23M	17.17M	13.02M	12.59M	10.6M	10.92M	3.54M	7.5M	9.16M	5.01M
Deferred Taxes	-44.17M	20.29M	-8.72M	1.27M	-5.77M	-8.42M	0	-80.38M	76.2M	0
Other Non-Cash Items	34M	24.46M	36.53M	22.51M	200.51M	-22.15M	5.48M	21.46M	267.82M	11.95M
Working Capital Changes	129.83M	-17.07M	18.34M	-107.2M	-606K	-44.21M	-31.29M	-13.01M	140K	5.2M
Change in Receivables	-44.12M	-30.93M	30.14M	35.27M	-5.53M	19.8M	-11K	-996K	48.67M	-6.46M
Change in Inventory	9.33M	-3.72M	-1.87M	9.05M	-316K	-291K	4.27M	-6.59M	-4.97M	-9.58M
Change in Payables	53.07M	5.86M	-6.44M	-33.61M	-15.15M	-36.48M	-28.7M	-10.11M	-29.35M	-1.26M
Cash from Investing+	-1.11B	45.54M	57.89M	-7.08M	-1.48M	512.8M	-18.52M	-42.67M	3.1M	-48.91M
Capital Expenditures	-26.71M	-2.86M	-666K	-5.51M	-1.48M	-10K	-53K	-274K	-628K	0
CapEx % of Revenue	0.08%	0.01%	0%	0.02%	0.01%	0%	0%	0%	0%	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-25M	48.4M	280K	80K	0	0	0	0	0	0
Cash from Financing+	576.58M	-94.41M	-110.89M	-81.35M	-157.84M	-468.55M	29.03M	-7.79M	-44.2M	-350K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-1.55M	-6.78M	-9.07M	-184K	-4.02M	-13.52M	-5.58M	-13.23M	-25.8M	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	117.18M	62.64M	61.5M	66.99M	88.99M	-65.58M	5.47M	78.32M	48.98M	26.41M
FCF Margin %	0.34%	0.14%	0.16%	0.21%	0.39%	-0.61%	0.05%	0.5%	0.32%	0.21%
FCF Growth %	3.07%	-0.47%	-0.02%	0.09%	0.33%	-1.74%	1.08%	13.32%	-0.37%	-0.46%
FCF per Share	7.80	4.09	3.92	4.17	5.03	-2.50	0.13	1.43	0.69	0.28
FCF Conversion (FCF/Net Income)	-1.90x	-0.74x	-0.61x	1.96x	-0.42x	2.33x	-4.31x	0.72x	-0.15x	-1.22x
Interest Paid	0	0	55.54M	48.44M	37.79M	17.6M	10.12M	7.75M	3.65M	2.6M
Taxes Paid	0	0	121K	6.47M	4.4M	0	0	0	4.03M	1.59M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-22.29%	-31.36%	-48.77%	18.93%	-156.1%	-49.61%	-1.62%	66.82%	-182.52%	-16.66%
Return on Invested Capital (ROIC)	-8.04%	2.16%	-4.33%	4.87%	-27.79%	-24.73%	5.32%	16.01%	-110.07%	-17.08%
Gross Margin	80.19%	80.83%	80.93%	94.07%	95.86%	85.41%	85.74%	88%	82.23%	68.61%
Net Margin	-22.1%	-19.46%	-26.92%	11.84%	-94.63%	-26.04%	-1.15%	70.17%	-218.28%	-17.27%
Debt / Equity	2.56x	2.87x	3.70x	2.57x	6.18x	1.61x	0.74x	0.30x	0.29x	0.33x
Interest Coverage	-0.69x	0.29x	-0.57x	0.63x	-3.33x	-5.16x	0.92x	4.95x	-72.05x	-8.05x
FCF Conversion	-1.90x	-0.74x	-0.61x	1.96x	-0.42x	2.33x	-4.31x	0.72x	-0.15x	-1.22x
Revenue Growth	-12.2%	33.02%	-16.49%	-18.11%	-26.38%	-52.91%	2.72%	40.73%	-2.67%	-17.83%

Revenue by Segment

	2016	2017	2018	2019	2020	2021	2022	2023	2024
Product	-	-	129.97M	108.81M	93.5M	109.42M	155.12M	149.45M	120.85M
Product Growth	-	-	-	-16.28%	-14.07%	17.03%	41.77%	-3.66%	-19.14%
INDOCIN Products	-	-	-	-	31.68M	60.56M	100.34M	87.22M	26.76M
INDOCIN Products Growth	-	-	-	-	-	91.13%	65.69%	-13.08%	-69.32%
Otrexup	-	-	-	-	-	-	11.15M	12.03M	8.84M
Otrexup Growth	-	-	-	-	-	-	-	7.88%	-26.48%
SPRIX Nasal Spray	-	-	-	-	11.08M	8.68M	9.11M	9.15M	7.62M
SPRIX Nasal Spray Growth	-	-	-	-	-	-21.68%	5.00%	0.44%	-16.68%
CAMBIA	-	-	-	-	-	-	-	8.07M	5.56M
CAMBIA Growth	-	-	-	-	-	-	-	-	-31.15%
Product and Service, Other	-	-	-	-	9.1M	-985K	-	185K	2.1M
Product and Service, Other Growth	-	-	-	-	-	-110.82%	-	-	1035.14%
Royalties And Milestones	-	-	26.06M	2.08M	1.52M	2.58M	2.4M	2.43M	2.01M
Royalties And Milestones Growth	-	-	-	-92.00%	-27.11%	69.78%	-6.82%	1.25%	-17.30%
Product, Other	-	-	-	-	-	5.03M	4.67M	1.42M	1.52M
Product, Other Growth	-	-	-	-	-	-	-7.10%	-69.72%	7.35%
Zipsor	27.54M	16.7M	16.39M	12.5M	13.29M	10.19M	3.36M	3.46M	-
Zipsor Growth	-	-39.36%	-1.87%	-23.73%	6.31%	-23.34%	-66.97%	2.85%	-
C A M B I A	31.27M	31.6M	35.8M	32.45M	28.35M	24.97M	24.72M	-	-
C A M B I A Growth	-	1.04%	13.31%	-9.36%	-12.64%	-11.92%	-1.01%	-	-
Other Revenue	-	-	-	-	-	-985K	-1.29M	-	-
Other Revenue Growth	-	-	-	-	-	-	-30.96%	-	-
Commercialization Agreement	-	-	155.74M	-	11.26M	-	-	-	-
Commercialization Agreement Growth	-	-	-	-	-	-	-	-	-
Commercialization Rights And Facilitation Services	-	-	100.04M	118.61M	-	-	-	-	-
Commercialization Rights And Facilitation Services Growth	-	-	-	18.57%	-	-	-	-	-
Neurology Product	-	-	110.27M	108.08M	-	-	-	-	-
Neurology Product Growth	-	-	-	-1.99%	-	-	-	-	-
Gralise	88.45M	77.03M	58.08M	63.12M	-	-	-	-	-
Gralise Growth	-	-12.90%	-24.61%	8.69%	-	-	-	-	-
Janssen Nucynta	-	-	18.94M	927K	-	-	-	-	-
Janssen Nucynta Growth	-	-	-	-95.11%	-	-	-	-	-
Revenue From Transfer Of Inventory From Commercialization Agreement	-	-	55.7M	-	-	-	-	-	-
Revenue From Transfer Of Inventory From Commercialization Agreement Growth	-	-	-	-	-	-	-	-	-
Lazanda	26.55M	15.01M	755K	-196K	-	-	-	-	-
Lazanda Growth	-	-43.46%	-94.97%	-125.96%	-	-	-	-	-
All Nucynta Products	281.26M	239.54M	-	-	-	-	-	-	-
All Nucynta Products Growth	-	-14.83%	-	-	-	-	-	-	-

Revenue by Geography

	2016	2017	2018	2019	2020	2021	2022	2023	2024
CANADA	-	-	-	-	1.5M	2.5M	1.9M	-	2M
CANADA Growth	-	-	-	-	-	66.67%	-24.00%	-	-

Frequently Asked Questions

Growth & Financials

Assertio Holdings, Inc. (ASRT) reported $137.4M in revenue for fiscal year 2024. This represents a 3% increase from $133.0M in 2011.

Assertio Holdings, Inc. (ASRT) saw revenue decline by 17.8% over the past year.

Assertio Holdings, Inc. (ASRT) reported a net loss of $28.9M for fiscal year 2024.

Dividend & Returns

Assertio Holdings, Inc. (ASRT) has a return on equity (ROE) of -16.7%. Negative ROE indicates the company is unprofitable.

Assertio Holdings, Inc. (ASRT) generated $13.3M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...

Assertio Holdings, Inc. (ASRT) 10-Year Financial Performance & Capital Metrics

ASRT • • Industrial / General

HealthcareSpecialty & Generic PharmaSpecialty PharmaceuticalsPain Management

Revenue $125M -17.8%
EBITDA $1M +100.6%
Net Income -$22M +93.5%
EPS (Diluted) -0.23 +95.1%
Gross Margin 68.61% -16.6%
EBITDA Margin 1.08% +100.8%
Operating Margin -19.59% +87.8%
Net Margin -17.27% +92.1%
ROE -16.66% +90.9%
ROIC -17.08% +84.5%
Debt/Equity 0.33 +15.7%
Interest Coverage -8.05 +88.8%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓FCF machine: 21.1% free cash flow margin
✓Momentum leader: RS Rating 99 (top 1%)
✓Trading near 52-week high

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Sales declining 11.5% over 5 years
✗Shares diluted 34.1% in last year

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-10.77%

5Y-11.45%

3Y4.02%

TTM9.21%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM57.77%

EPS CAGR

10Y-

5Y-

3Y-

TTM57.45%

ROCE

10Y Avg-15.64%

5Y Avg-24.01%

3Y Avg-31.08%

Latest-13.48%

Peer Comparison

Pain Management

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
COLLCollegium Pharmaceutical, Inc.	1.48B	46.90	25.22	11.41%	7.72%	21.27%	13.71%	3.75
PRFXPainReform Ltd.	3.21M	0.82	-0.03			-48.4%		0.02
PCRXPacira BioSciences, Inc.	848.72M	20.65	-9.60	3.85%	2.99%	2.95%	21.06%	0.82
APUSApimeds Pharmaceuticals US, Inc	21.76M	1.73	-15.73			-63.2%
ASRTAssertio Holdings, Inc.	71.42M	11.13	-48.39	-17.83%	-21.06%	-27.34%	36.98%	0.33

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	342.74M	455.9M	380.72M	311.77M	229.53M	108.08M	111.01M	156.23M	152.07M	124.96M
Revenue Growth %	-0.12%	0.33%	-0.16%	-0.18%	-0.26%	-0.53%	0.03%	0.41%	-0.03%	-0.18%
Cost of Goods Sold+	67.9M	87.41M	72.6M	18.48M	9.51M	15.77M	15.83M	18.75M	27.02M	39.23M
COGS % of Revenue	0.2%	0.19%	0.19%	0.06%	0.04%	0.15%	0.14%	0.12%	0.18%	0.31%
Gross Profit+	274.84M	368.48M	308.13M	293.29M	220.02M	92.3M	95.18M	137.49M	125.05M	85.73M
Gross Margin %	0.8%	0.81%	0.81%	0.94%	0.96%	0.85%	0.86%	0.88%	0.82%	0.69%
Gross Profit Growth %	-0.27%	0.34%	-0.16%	-0.05%	-0.25%	-0.58%	0.03%	0.44%	-0.09%	-0.31%
Operating Expenses+	355.14M	343.97M	337.06M	229.03M	414.45M	174.46M	85.76M	98.08M	368.58M	110.21M
OpEx % of Revenue	1.04%	0.75%	0.89%	0.73%	1.81%	1.61%	0.77%	0.63%	2.42%	0.88%
Selling, General & Admin	199.35M	204.5M	195.69M	119.22M	110.44M	104.22M	56.55M	48.1M	69.74M	76.95M
SG&A % of Revenue	0.58%	0.45%	0.51%	0.38%	0.48%	0.96%	0.51%	0.31%	0.46%	0.62%
Research & Development	72.44M	32.63M	38.62M	8.04M	10.11M	4.21M	0	0	2.84M	3.82M
R&D % of Revenue	0.21%	0.07%	0.1%	0.03%	0.04%	0.04%	-	-	0.02%	0.03%
Other Operating Expenses	599K	106.84M	102.75M	101.77M	293.9M	66.03M	29.2M	49.98M	296M	29.44M
Operating Income+	-50.4M	24.51M	-42.18M	43.66M	-194.43M	-82.16M	9.42M	39.41M	-243.54M	-24.48M
Operating Margin %	-0.15%	0.05%	-0.11%	0.14%	-0.85%	-0.76%	0.08%	0.25%	-1.6%	-0.2%
Operating Income Growth %	-1.21%	1.49%	-2.72%	2.04%	-5.45%	0.58%	1.11%	3.18%	-7.18%	0.9%
EBITDA+	32.94M	133.88M	63.32M	150.09M	-91.48M	-55.72M	38.54M	72.8M	-215.31M	1.35M
EBITDA Margin %	0.1%	0.29%	0.17%	0.48%	-0.4%	-0.52%	0.35%	0.47%	-1.42%	0.01%
EBITDA Growth %	-0.87%	3.06%	-0.53%	1.37%	-1.61%	0.39%	1.69%	0.89%	-3.96%	1.01%
D&A (Non-Cash Add-back)	83.34M	109.38M	105.5M	106.43M	102.95M	26.43M	29.11M	33.4M	28.23M	25.83M
EBIT	-49.8M	19.22M	-30.37M	106.86M	-5.11M	-42.71M	9.67M	56.77M	24.94M	-20.68M
Net Interest Income+	-72.84M	-83.23M	-73.55M	-67.56M	-58.39M	-15.93M	-10.22M	-7.96M	-3.38M	182K
Interest Income	599K	485K	0	1.2M	0	0	0	0	0	3.22M
Interest Expense	73.44M	83.72M	73.55M	68.76M	58.39M	15.93M	10.22M	7.96M	3.38M	3.04M
Other Income/Expense	-72.84M	-89.01M	-61.74M	-5.68M	-17.49M	71.38M	-9.98M	-8.24M	-10.52M	2.95M
Pretax Income+	-123.24M	-64.5M	-103.92M	37.98M	-211.92M	-10.78M	-553K	31.17M	-254.05M	-21.53M
Pretax Margin %	-0.36%	-0.14%	-0.27%	0.12%	-0.92%	-0.1%	-0%	0.2%	-1.67%	-0.17%
Income Tax+	-47.5M	24.22M	-1.43M	1.07M	5.28M	17.37M	728K	-78.46M	77.89M	52K
Effective Tax Rate %	0.61%	1.38%	0.99%	0.97%	1.02%	2.61%	2.32%	3.52%	1.31%	1%
Net Income+	-75.74M	-88.72M	-102.5M	36.91M	-217.2M	-28.14M	-1.28M	109.63M	-331.94M	-21.58M
Net Margin %	-0.22%	-0.19%	-0.27%	0.12%	-0.95%	-0.26%	-0.01%	0.7%	-2.18%	-0.17%
Net Income Growth %	-1.57%	-0.17%	-0.16%	1.36%	-6.88%	0.87%	0.95%	86.58%	-4.03%	0.93%
Net Income (Continuing)	-75.74M	-88.72M	-102.5M	36.91M	-217.2M	-28.14M	-1.28M	109.63M	-331.94M	-21.58M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-5.04	-5.79	-6.54	2.30	-12.29	-1.07	-0.03	2.03	-4.67	-0.23
EPS Growth %	-1.61%	-0.15%	-0.13%	1.35%	-6.34%	0.91%	0.97%	69.35%	-3.3%	0.95%
EPS (Basic)	-5.04	-5.80	-6.54	2.31	-12.29	-1.07	-0.03	2.33	-4.67	-0.23
Diluted Shares Outstanding	15.03M	15.32M	15.68M	16.05M	17.68M	26.21M	43.17M	54.67M	71.03M	95.27M
Basic Shares Outstanding	15.03M	15.3M	15.68M	15.95M	17.68M	26.21M	43.17M	47M	71.03M	95.27M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	316.65M	307.66M	231.72M	215.92M	103.95M	94.25M	103.5M	132.26M	171.06M	202.55M
Cash & Short-Term Investments	209.77M	177.42M	128.09M	110.95M	42.11M	20.79M	36.81M	64.94M	73.44M	100.05M
Cash Only	209.77M	177.42M	128.09M	110.95M	42.11M	20.79M	36.81M	64.94M	73.44M	50.59M
Short-Term Investments	0	0	0	0	0	0	0	0	0	49.47M
Accounts Receivable	78.05M	102.59M	72.48M	37.21M	42.74M	44.35M	43.75M	45.36M	47.66M	54.12M
Days Sales Outstanding	83.11	82.13	69.49	43.56	67.97	149.78	143.85	105.96	114.4	158.08
Inventory	10.49M	13.03M	13.04M	3.4M	3.41M	11.71M	7.49M	13.7M	37.69M	38.31M
Days Inventory Outstanding	56.41	54.42	65.57	67.09	131.02	271.04	172.66	266.64	509.08	356.45
Other Current Assets	0	0	0	0	0	0	608K	0	299K	10.07M
Total Non-Current Assets+	1.05B	917.67M	806.9M	716.95M	423.22M	209.02M	223.05M	281.65M	115.36M	82.18M
Property, Plant & Equipment	14.79M	15.53M	13.02M	13.06M	3.5M	4.39M	2.26M	881K	2.04M	1.71M
Fixed Asset Turnover	23.17x	29.36x	29.23x	23.86x	65.64x	24.61x	49.08x	177.34x	74.58x	73.03x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	1.01B	902.15M	793.87M	692.1M	400.54M	200.08M	216.05M	198M	111.33M	80.47M
Long-Term Investments	-7.68M	0	0	11.78M	13.06M	1.58M	1.58M	268K	0	0
Other Non-Current Assets	7.68M	0	0	7.81M	6.12M	2.97M	3.15M	2.3M	1.99M	1K
Total Assets+	1.36B	1.23B	1.04B	932.87M	527.17M	303.27M	326.55M	413.91M	286.42M	284.73M
Asset Turnover	0.25x	0.37x	0.37x	0.33x	0.44x	0.36x	0.34x	0.38x	0.53x	0.44x
Asset Growth %	0.92%	-0.1%	-0.15%	-0.1%	-0.43%	-0.42%	0.08%	0.27%	-0.31%	-0.01%
Total Current Liabilities+	196.79M	221.77M	224.4M	124.9M	184.55M	132.69M	135.02M	95.32M	93.44M	114.69M
Accounts Payable	12.8M	14.86M	14.73M	6.14M	16.19M	14.81M	6.68M	5.99M	13.44M	14.74M
Days Payables Outstanding	68.84	62.03	74.07	121.26	621.82	342.69	154.12	116.64	181.54	137.12
Short-Term Debt	563.47M	466.05M	82.5M	120M	80M	11.94M	12.17M	470K	0	0
Deferred Revenue (Current)	1000K	1000K	1000K	-1000K	1000K	0	0	0	0	0
Other Current Liabilities	-559.31M	-460.52M	13.29M	2.71M	-82.5M	20.02M	47.65M	30.36M	6.09M	96.36M
Current Ratio	1.61x	1.39x	1.03x	1.73x	0.56x	0.71x	0.77x	1.39x	1.83x	1.77x
Quick Ratio	1.56x	1.33x	0.97x	1.70x	0.54x	0.62x	0.71x	1.24x	1.43x	1.43x
Cash Conversion Cycle	70.69	74.53	60.99	-10.61	-422.83	78.13	162.39	255.97	441.94	377.41
Total Non-Current Liabilities+	851.58M	752.78M	644.71M	587.63M	284.66M	115.07M	89.11M	92.87M	54.97M	48.96M
Long-Term Debt	800.33M	718.78M	544.23M	446.11M	271.26M	72.16M	61.32M	66.4M	38.21M	38.81M
Capital Lease Obligations	0	0	0	0	4.82M	2.81M	397K	0	1.47M	1.12M
Deferred Tax Liabilities	0	0	0	0	0	0	0	4.27M	4.55M	0
Other Non-Current Liabilities	22.24M	28.53M	14.3M	20.39M	8.58M	40.1M	27.4M	22.2M	10.74M	9.03M
Total Liabilities	1.05B	974.55M	869.11M	712.53M	469.21M	247.76M	224.13M	188.19M	148.42M	163.65M
Total Debt+	806.51M	718.78M	626.73M	566.11M	358.17M	89.6M	75.87M	66.87M	39.68M	40.27M
Net Debt	596.74M	541.36M	498.64M	455.16M	316.06M	68.81M	39.06M	1.93M	-33.77M	-10.32M
Debt / Equity	2.56x	2.87x	3.70x	2.57x	6.18x	1.61x	0.74x	0.30x	0.29x	0.33x
Debt / EBITDA	24.48x	5.37x	9.90x	3.77x	-	-	1.97x	0.92x	-	29.76x
Net Debt / EBITDA	18.11x	4.04x	7.87x	3.03x	-	-	1.01x	0.03x	-	-7.63x
Interest Coverage	-0.69x	0.29x	-0.57x	0.63x	-3.33x	-5.16x	0.92x	4.95x	-72.05x	-8.05x
Total Equity+	315.06M	250.79M	169.51M	220.34M	57.96M	55.51M	102.41M	225.72M	138M	121.08M
Equity Growth %	-0.14%	-0.2%	-0.32%	0.3%	-0.74%	-0.04%	0.84%	1.2%	-0.39%	-0.12%
Book Value per Share	20.96	16.37	10.81	13.73	3.28	2.12	2.37	4.13	1.94	1.27
Total Shareholders' Equity	315.06M	250.79M	169.51M	220.34M	57.96M	55.51M	102.41M	225.72M	138M	121.08M
Common Stock	264.51M	291.63M	313.86M	6K	8K	3K	4K	5K	9K	9K
Retained Earnings	-28.02M	-116.74M	-219.51M	-182.6M	-399.8M	-427.94M	-429.23M	-319.6M	-651.54M	-673.12M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-54K	-19K	-5K	-5K	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	143.89M	65.5M	62.17M	72.5M	90.47M	-65.57M	5.52M	78.6M	49.6M	26.41M
Operating CF Margin %	0.42%	0.14%	0.16%	0.23%	0.39%	-0.61%	0.05%	0.5%	0.33%	0.21%
Operating CF Growth %	3.57%	-0.54%	-0.05%	0.17%	0.25%	-1.72%	1.08%	13.23%	-0.37%	-0.47%
Net Income	-75.74M	-88.72M	-102.5M	36.91M	-217.2M	-28.14M	-1.28M	109.63M	-331.94M	-21.58M
Depreciation & Amortization	85.74M	109.38M	105.5M	106.43M	102.95M	26.43M	29.08M	33.4M	28.23M	25.83M
Stock-Based Compensation	14.23M	17.17M	13.02M	12.59M	10.6M	10.92M	3.54M	7.5M	9.16M	5.01M
Deferred Taxes	-44.17M	20.29M	-8.72M	1.27M	-5.77M	-8.42M	0	-80.38M	76.2M	0
Other Non-Cash Items	34M	24.46M	36.53M	22.51M	200.51M	-22.15M	5.48M	21.46M	267.82M	11.95M
Working Capital Changes	129.83M	-17.07M	18.34M	-107.2M	-606K	-44.21M	-31.29M	-13.01M	140K	5.2M
Change in Receivables	-44.12M	-30.93M	30.14M	35.27M	-5.53M	19.8M	-11K	-996K	48.67M	-6.46M
Change in Inventory	9.33M	-3.72M	-1.87M	9.05M	-316K	-291K	4.27M	-6.59M	-4.97M	-9.58M
Change in Payables	53.07M	5.86M	-6.44M	-33.61M	-15.15M	-36.48M	-28.7M	-10.11M	-29.35M	-1.26M
Cash from Investing+	-1.11B	45.54M	57.89M	-7.08M	-1.48M	512.8M	-18.52M	-42.67M	3.1M	-48.91M
Capital Expenditures	-26.71M	-2.86M	-666K	-5.51M	-1.48M	-10K	-53K	-274K	-628K	0
CapEx % of Revenue	0.08%	0.01%	0%	0.02%	0.01%	0%	0%	0%	0%	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-25M	48.4M	280K	80K	0	0	0	0	0	0
Cash from Financing+	576.58M	-94.41M	-110.89M	-81.35M	-157.84M	-468.55M	29.03M	-7.79M	-44.2M	-350K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-1.55M	-6.78M	-9.07M	-184K	-4.02M	-13.52M	-5.58M	-13.23M	-25.8M	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	117.18M	62.64M	61.5M	66.99M	88.99M	-65.58M	5.47M	78.32M	48.98M	26.41M
FCF Margin %	0.34%	0.14%	0.16%	0.21%	0.39%	-0.61%	0.05%	0.5%	0.32%	0.21%
FCF Growth %	3.07%	-0.47%	-0.02%	0.09%	0.33%	-1.74%	1.08%	13.32%	-0.37%	-0.46%
FCF per Share	7.80	4.09	3.92	4.17	5.03	-2.50	0.13	1.43	0.69	0.28
FCF Conversion (FCF/Net Income)	-1.90x	-0.74x	-0.61x	1.96x	-0.42x	2.33x	-4.31x	0.72x	-0.15x	-1.22x
Interest Paid	0	0	55.54M	48.44M	37.79M	17.6M	10.12M	7.75M	3.65M	2.6M
Taxes Paid	0	0	121K	6.47M	4.4M	0	0	0	4.03M	1.59M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-22.29%	-31.36%	-48.77%	18.93%	-156.1%	-49.61%	-1.62%	66.82%	-182.52%	-16.66%
Return on Invested Capital (ROIC)	-8.04%	2.16%	-4.33%	4.87%	-27.79%	-24.73%	5.32%	16.01%	-110.07%	-17.08%
Gross Margin	80.19%	80.83%	80.93%	94.07%	95.86%	85.41%	85.74%	88%	82.23%	68.61%
Net Margin	-22.1%	-19.46%	-26.92%	11.84%	-94.63%	-26.04%	-1.15%	70.17%	-218.28%	-17.27%
Debt / Equity	2.56x	2.87x	3.70x	2.57x	6.18x	1.61x	0.74x	0.30x	0.29x	0.33x
Interest Coverage	-0.69x	0.29x	-0.57x	0.63x	-3.33x	-5.16x	0.92x	4.95x	-72.05x	-8.05x
FCF Conversion	-1.90x	-0.74x	-0.61x	1.96x	-0.42x	2.33x	-4.31x	0.72x	-0.15x	-1.22x
Revenue Growth	-12.2%	33.02%	-16.49%	-18.11%	-26.38%	-52.91%	2.72%	40.73%	-2.67%	-17.83%

Revenue by Segment

	2016	2017	2018	2019	2020	2021	2022	2023	2024
Product	-	-	129.97M	108.81M	93.5M	109.42M	155.12M	149.45M	120.85M
Product Growth	-	-	-	-16.28%	-14.07%	17.03%	41.77%	-3.66%	-19.14%
INDOCIN Products	-	-	-	-	31.68M	60.56M	100.34M	87.22M	26.76M
INDOCIN Products Growth	-	-	-	-	-	91.13%	65.69%	-13.08%	-69.32%
Otrexup	-	-	-	-	-	-	11.15M	12.03M	8.84M
Otrexup Growth	-	-	-	-	-	-	-	7.88%	-26.48%
SPRIX Nasal Spray	-	-	-	-	11.08M	8.68M	9.11M	9.15M	7.62M
SPRIX Nasal Spray Growth	-	-	-	-	-	-21.68%	5.00%	0.44%	-16.68%
CAMBIA	-	-	-	-	-	-	-	8.07M	5.56M
CAMBIA Growth	-	-	-	-	-	-	-	-	-31.15%
Product and Service, Other	-	-	-	-	9.1M	-985K	-	185K	2.1M
Product and Service, Other Growth	-	-	-	-	-	-110.82%	-	-	1035.14%
Royalties And Milestones	-	-	26.06M	2.08M	1.52M	2.58M	2.4M	2.43M	2.01M
Royalties And Milestones Growth	-	-	-	-92.00%	-27.11%	69.78%	-6.82%	1.25%	-17.30%
Product, Other	-	-	-	-	-	5.03M	4.67M	1.42M	1.52M
Product, Other Growth	-	-	-	-	-	-	-7.10%	-69.72%	7.35%
Zipsor	27.54M	16.7M	16.39M	12.5M	13.29M	10.19M	3.36M	3.46M	-
Zipsor Growth	-	-39.36%	-1.87%	-23.73%	6.31%	-23.34%	-66.97%	2.85%	-
C A M B I A	31.27M	31.6M	35.8M	32.45M	28.35M	24.97M	24.72M	-	-
C A M B I A Growth	-	1.04%	13.31%	-9.36%	-12.64%	-11.92%	-1.01%	-	-
Other Revenue	-	-	-	-	-	-985K	-1.29M	-	-
Other Revenue Growth	-	-	-	-	-	-	-30.96%	-	-
Commercialization Agreement	-	-	155.74M	-	11.26M	-	-	-	-
Commercialization Agreement Growth	-	-	-	-	-	-	-	-	-
Commercialization Rights And Facilitation Services	-	-	100.04M	118.61M	-	-	-	-	-
Commercialization Rights And Facilitation Services Growth	-	-	-	18.57%	-	-	-	-	-
Neurology Product	-	-	110.27M	108.08M	-	-	-	-	-
Neurology Product Growth	-	-	-	-1.99%	-	-	-	-	-
Gralise	88.45M	77.03M	58.08M	63.12M	-	-	-	-	-
Gralise Growth	-	-12.90%	-24.61%	8.69%	-	-	-	-	-
Janssen Nucynta	-	-	18.94M	927K	-	-	-	-	-
Janssen Nucynta Growth	-	-	-	-95.11%	-	-	-	-	-
Revenue From Transfer Of Inventory From Commercialization Agreement	-	-	55.7M	-	-	-	-	-	-
Revenue From Transfer Of Inventory From Commercialization Agreement Growth	-	-	-	-	-	-	-	-	-
Lazanda	26.55M	15.01M	755K	-196K	-	-	-	-	-
Lazanda Growth	-	-43.46%	-94.97%	-125.96%	-	-	-	-	-
All Nucynta Products	281.26M	239.54M	-	-	-	-	-	-	-
All Nucynta Products Growth	-	-14.83%	-	-	-	-	-	-	-

Revenue by Geography

	2016	2017	2018	2019	2020	2021	2022	2023	2024
CANADA	-	-	-	-	1.5M	2.5M	1.9M	-	2M
CANADA Growth	-	-	-	-	-	66.67%	-24.00%	-	-

Frequently Asked Questions

Growth & Financials

Assertio Holdings, Inc. (ASRT) reported $137.4M in revenue for fiscal year 2024. This represents a 3% increase from $133.0M in 2011.

Assertio Holdings, Inc. (ASRT) saw revenue decline by 17.8% over the past year.

Assertio Holdings, Inc. (ASRT) reported a net loss of $28.9M for fiscal year 2024.

Dividend & Returns

Assertio Holdings, Inc. (ASRT) has a return on equity (ROE) of -16.7%. Negative ROE indicates the company is unprofitable.

Assertio Holdings, Inc. (ASRT) generated $13.3M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.